CIK 1844645
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 84.03% | 12 |
| Unclassified | 15.97% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | PCVX | Vaxcyte, Inc. | Health Care | 28.51% |
| 2 | OCS | OCULIS HOLDING AG | Unclassified | 15.97% |
| 3 | EVMN | Evommune, Inc. | Health Care | 15.83% |
| 4 | ARQT | Arcutis Biotherapeutics, Inc. | Health Care | 11.42% |
| 5 | TRVI | Trevi Therapeutics, Inc. | Health Care | 6.63% |
| 6 | IMNM | Immunome Inc. | Health Care | 5.73% |
| 7 | MPLT | MapLight Therapeutics, Inc. | Health Care | 4.44% |
| 8 | ZBIO | Zenas BioPharma, Inc. | Health Care | 4.14% |
| 9 | BIOA | BioAge Labs, Inc. | Health Care | 4.08% |
| 10 | AVTX | Avalo Therapeutics, Inc. | Health Care | 1.58% |
12/13 names classified · sector 84.0% of weight · industry 84.0% · mkt cap 84.0%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 84.0% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/13 names) · unclassified 100.0%: PCVX, OCS, EVMN, ARQT, TRVI, IMNM, MPLT, ZBIO, BIOA, AVTX +3 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | PCVXVAXCYTE INC | 1,372,425 | $80M | 28.5% | HOLD |
| 2 | OCSOCULIS HOLDING AG | 1,680,283 | $45M | 16.0% | TRIM −27% |
| 3 | EVMNEVOMMUNE INC | 1,926,943 | $44M | 15.8% | HOLD |
| 4 | ARQTARCUTIS BIOTHERAPEUTICS INC | 1,355,892 | $32M | 11.4% | HOLD |
| 5 | TRVITREVI THERAPEUTICS INC | 1,553,726 | $19M | 6.6% | ADD 24% |
| 6 | IMNMIMMUNOME INC | 732,512 | $16M | 5.7% | HOLD |
| 7 | MPLTMAPLIGHT THERAPEUTICS INC | 611,447 | $12M | 4.4% | HOLD |
| 8 | ZBIOZENAS BIOPHARMA INC | 591,991 | $12M | 4.1% | HOLD |
| 9 | BIOABIOAGE LABS INC | 653,374 | $11M | 4.1% | HOLD |
| 10 | AVTXAVALO THERAPEUTICS INC | 295,933 | $4M | 1.6% | NEW |
| 11 | RLYBRALLYBIO CORP | 300,579 | $3M | 1.0% | NEW |
| 12 | RXRXRECURSION PHARMACEUTICALS IN | 595,518 | $2M | 0.7% | HOLD |
| 13 | BOLTBOLT BIOTHERAPEUTICS INC | 42,581 | $172,027 | 0.1% | TRIM −55% |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| PCVXVAXCYTE INC | 704K | 711K | 1.3M | 1.4M | 1.4M | 1.4M | $80M |
| OCSOCULIS HOLDING AG | 1.7M | 2.3M | 2.3M | 2.3M | 2.3M | 1.7M | $45M |
| EVMNEVOMMUNE INC | — | — | — | — | 1.9M | 1.9M | $44M |
| ARQTARCUTIS BIOTHERAPEUTICS INC | 2.1M | 2.1M | 2.1M | 2.1M | 1.4M | 1.4M | $32M |
| TRVITREVI THERAPEUTICS INC | — | — | 1.1M | 1.3M | 1.3M | 1.6M | $19M |
| IMNMIMMUNOME INC | — | — | — | 503K | 733K | 733K | $16M |
| MPLTMAPLIGHT THERAPEUTICS INC | — | — | — | — | 611K | 611K | $12M |
| ZBIOZENAS BIOPHARMA INC | 737K | 737K | 779K | 779K | 592K | 592K | $12M |
| BIOABIOAGE LABS INC | 653K | 653K | 653K | 653K | 653K | 653K | $11M |
| AVTXAVALO THERAPEUTICS INC | — | — | — | — | — | 296K | $4M |
| RLYBRALLYBIO CORP | — | — | — | — | — | 301K | $3M |
| RXRXRECURSION PHARMACEUTICALS IN | 596K | 596K | 596K | 596K | 596K | 596K | $2M |
| BOLTBOLT BIOTHERAPEUTICS INC | — | — | 95K | 95K | 95K | 43K | $172,027 |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
